他汀类药物治疗与 2 型糖尿病个体的表观遗传修饰有关。
Statin therapy is associated with epigenetic modifications in individuals with Type 2 diabetes.
机构信息
Department of Clinical Sciences, Epigenetics & Diabetes Unit, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö 205 02, Sweden.
Department of Public Health & Caring Sciences, Uppsala University, Uppsala 75122, Sweden.
出版信息
Epigenomics. 2021 Jun;13(12):919-925. doi: 10.2217/epi-2020-0442. Epub 2021 May 5.
Statins lower cholesterol and reduce the risk of cardiovascular disease. However, the exact mechanisms of statins remain unknown. We investigated whether statin therapy associates with epigenetics in Type 2 diabetes (T2D) patients. DNA methylation was analyzed in blood from newly diagnosed T2D patients in All New Diabetics in Scania (ANDIS) and a replication cohort All New Diabetics in Uppsala County (ANDiU). Seventy-nine sites were differentially methylated between cases on statins and controls (false discovery rate <5%) in ANDIS. These include previously statin-associated methylation sites annotated to (cg17901584), (cg27243685) and (cg05119988). Differential methylation of two sites related to cholesterol biosynthesis and immune response, cg17901584 () and cg23011663 (), were replicated in ANDiU. Statin therapy associates with epigenetic modifications in T2D patients.
他汀类药物降低胆固醇并降低心血管疾病的风险。然而，他汀类药物的确切机制尚不清楚。我们研究了他汀类药物治疗是否与 2 型糖尿病（T2D）患者的表观遗传学有关。在 All New Diabetics in Scania（ANDIS）和 All New Diabetics in Uppsala County（ANDiU）的新诊断 T2D 患者的血液中分析了 DNA 甲基化。在 ANDIS 中，他汀类药物治疗组与对照组之间有 79 个位点存在差异甲基化（假发现率<5%）。其中包括先前注释为（cg17901584）、（cg27243685）和（cg05119988）的他汀类药物相关甲基化位点。胆固醇生物合成和免疫反应相关的两个位点 cg17901584（）和 cg23011663（）的差异甲基化在 ANDiU 中得到了复制。他汀类药物治疗与 T2D 患者的表观遗传学改变有关。
Zotero 插件